No Data
No Data
Hualing Pharmaceuticals announced at the 2024 ADA Scientific Conference the potential of using Dapagliflozin in combination with SGLT-2 inhibitors.
Shanghai, June 24, 2024 / PRNewswire / - Hualei Medicine ("the Company", Stock Code: 2552.HK) announced today that it demonstrated multiple basic research results at the 84th American Diabetes Association (ADA) Scientific Sessions, including pioneering innovative drugs GKA Duvoglitazone which reduces blood glucose levels by promoting the secretion of insulin and GLP-1 through dual activation of glucose kinase. Duvoglitazone and SGLT-2 inhibitor Caglitinib are used in combination. This research was conducted by the Company and its wholly-owned subsidiary, Nanjing Shengderui'er Pharmaceutical Technology Co., Ltd. (Shengderui'er).
Hua Medicine (Shanghai) Ltd.'s (HKG:2552) CEO Compensation Is Looking A Bit Stretched At The Moment
Key Insights Hua Medicine (Shanghai) to hold its Annual General Meeting on 27th of June Total pay for CEO Li Chen includes CN¥5.74m salary The overall pay is 310% above the industry average Hua
HKEX Buzz: Hualei Pharmaceutical-B (02552) rose more than 4% and will exhibit multiple research achievements at the American Diabetes Association conference in 2024.
Hua Ling Pharmaceutical - B (02552) rose more than 4%, as of the time of publication, up 4.43% to HKD 1.65, with a turnover of HKD 1.684 million.
HUA MEDICINE-B: Annual Report 2023
Hualing Pharmaceutical (02552) announces 2023 results: R&D expenses of about 172 million yuan to actively promote the overseas market layout of second-generation GKA
On March 28, Hualing Pharmaceutical (02552) announced its 2023 results
HUA MEDICINE-B: ANNUAL RESULTS ANNOUNCEMENT FORTHE YEAR ENDED DECEMBER 31, 2023
No Data